Epidemiology and treatment of multiple sclerosis in elderly populations

Epidemiology and treatment of multiple sclerosis in elderly populations

Publication date: Apr 19, 2019

Marrie, R. A. , Yu, N. , Blanchard, J. , Leung, S. Elliott, L.

The rising prevalence and changing age distribution of multiple sclerosis in Manitoba.

Finlayson, M. Concerns about the future among older adults with multiple sclerosis.

Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis.

Scalfari, A. , Neuhaus, A. , Daumer, M. , Muraro, P. A. Ebers, G. C. Onset of secondary progressive phase and long-term evolution of multiple sclerosis.

5. Koch-Henriksen, N. , Laursen, B. , Stenager, E. Magyari, M. Excess mortality among patients with multiple sclerosis in Denmark has dropped significantly over the past six decades: a population based study.

Hirst, C. , Swingler, R. , Compston, D. A. , Ben-Shlomo, Y. Robertson, N. P. Survival and cause of death in multiple sclerosis: a prospective population-based study.

Hurwitz, B. J. Analysis of current multiple sclerosis registries.

Lunde, H. M. B. , Assmus, J. , Myhr, K. M. , Bo, L. Grytten, N. Survival and cause of death in multiple sclerosis: a 60-year longitudinal population study.

Relative mortality and survival in multiple sclerosis: findings from British Columbia.

Minden, S. L. , Frankel, D. , Hadden, L. S. , Srinath, K. P. Perloff, J. N. Disability in elderly people with multiple sclerosis: an analysis of baseline data from the Sonya Slifka Longitudinal Multiple Sclerosis Study.

Temporal trends in multiple sclerosis prevalence and incidence in a large population.

Grytten, N. , Torkildsen, O. Myhr, K. M. Time trends in the incidence and prevalence of multiple sclerosis in Norway during eight decades.

The increasing prevalence of multiple sclerosis in New Zealand.

Multiple sclerosis prevalence in the United States commercially insured population.

The changing face of multiple sclerosis: prevalence and incidence in an aging population.

Barnett, M. H. , Williams, D. B. , Day, S. , Macaskill, P. McLeod, J. G. Progressive increase in incidence and prevalence of multiple sclerosis in Newcastle, Australia: a 35-year study.

Trends in the epidemiology of multiple sclerosis in Greater Hobart, Tasmania: 1951 to 2009.

Sarasoja, T. , Wikstrom, J. , Paltamaa, J. , Hakama, M. Sumelahti, M. L. Occurrence of multiple sclerosis in central Finland: a regional and temporal comparison during 30 years.

Incidence and prevalence of multiple sclerosis in Olmsted County, Minnesota, 1985-2000.

A systematic assessment of prevalence, incidence and regional distribution of multiple sclerosis in Bavaria from 2006 to 2015.

Multiple sclerosis incidence and prevalence trends in the province of Padua, northeast Italy, 1965-2018.

Ribbons, K. , Lea, R. , Tiedeman, C. , Mackenzie, L. Lechner-Scott, J. Ongoing increase in incidence and prevalence of multiple sclerosis in Newcastle, Australia: a 50-year study.

The changing demographic pattern of multiple sclerosis epidemiology.

Bermel, R. A. , Rae-Grant, A. D. Fox, R. J. Diagnosing multiple sclerosis at a later age: more than just progressive myelopathy.

Poser, C. M. Brinar, V. V. Diagnostic criteria for multiple sclerosis: an historical review.

The diagnostic criteria for multiple sclerosis: from Charcot to McDonald.

Polliack, M. L. , Barak, Y. Achiron, A. Late-onset multiple sclerosis.

Delalande, S. , De Seze, J. , Ferriby, D. , Stojkovic, T. Vermersch, P. Late onset multiple sclerosis [French].

Tremlett, H. Devonshire, V. Is late-onset multiple sclerosis associated with a worse outcome?

Hooge, J. P. Redekop, W. K. Multiple sclerosis with very late onset.

31. Koch-Henriksen, N. , Thygesen, L. C. , Stenager, E. , Laursen, B. Magyari, M. Incidence of MS has increased markedly over six decades in Denmark particularly with late onset and in women.

A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: overview.

Mortality and comorbidities in patients with multiple sclerosis compared with a population without multiple sclerosis: an observational study using the US Department of Defense administrative claims database.

Manouchehrinia, A. , Tanasescu, R. , Tench, C. R. Constantinescu, C. S. Mortality in multiple sclerosis: meta-analysis of standardised mortality ratios.

Mortality in patients with multiple sclerosis.

Survival in commercially insured multiple sclerosis patients and comparator subjects in the U. S. Mult.

38. Bronnum-Hansen, H. , Koch-Henriksen, N. Stenager, E. Trends in survival and cause of death in Danish patients with multiple sclerosis.

Ragonese, P. , Aridon, P. , Salemi, G. , D’Amelio, M. Savettieri, G. Mortality in multiple sclerosis: a review.

Warren, S. A. , Janzen, W. , Warren, K. G. , Svenson, L. W. Schopflocher, D. P. Multiple sclerosis mortality rates in Canada, 1975-2009.

Amezcua, L. , Rivas, E. , Joseph, S. , Zhang, J. Liu, L. Multiple sclerosis mortality by race/ethnicity, age, sex, and time period in the United States, 1999-2015.

Hemmer, B. , Kerschensteiner, M. Korn, T. Role of the innate and adaptive immune responses in the course of multiple sclerosis.

The immune pathogenesis of multiple sclerosis.

An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.

Fletcher, J. M. , Lalor, S. J. , Sweeney, C. M. , Tubridy, N. Mills, K. H. G. T cells in multiple sclerosis and experimental autoimmune encephalomyelitis.

A B cell-driven autoimmune pathway leading to pathological hallmarks of progressive multiple sclerosis in the marmoset experimental autoimmune encephalomyelitis model.

Reich, D. S. , Lucchinetti, C. F. Calabresi, P. A. Multiple sclerosis.

Gandhi, R. , Laroni, A. Weiner, H. L. Role of the innate immune system in the pathogenesis of multiple sclerosis.

Kasper, L. H. Shoemaker, J. Multiple sclerosis immunology: the healthy immune system versus the MS immune system.

The relation between inflammation and neurodegeneration in multiple sclerosis brains.

Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque.

Lassmann, H. , van Horssen, J. Mahad, D. Progressive multiple sclerosis: pathology and pathogenesis.

Stephenson, E. , Nathoo, N. , Mahjoub, Y. , Dunn, J. F. Yong, V. W. Iron in multiple sclerosis: roles in neurodegeneration and repair.

Grebenciucova, E. Berger, J. R. Immunosenescence: the role of aging in the predisposition to neuro-infectious complications arising from the treatment of multiple sclerosis.

Lassmann, H. Pathology and disease mechanisms in different stages of multiple sclerosis.

Aging and multiple sclerosis.

Elevated ATG5 expression in autoimmune demyelination and multiple sclerosis.

Peterson, J. W. Trapp, B. D. Neuropathobiology of multiple sclerosis.

Dutta, R. Trapp, B. D. Relapsing and progressive forms of multiple sc

Concepts Keywords
Aging
Aging Population
Australia
Autoimmune
Autoimmune Disease
Autophagy
Bavaria
British Columbia
Canada
Cognitive
Colombo
Comorbidities
Comorbidity
Comparator
Cross
Danish
Delalande
Demographic
Demyelination
Denmark
Disability
Epidemiology
Evolution
Finland
Frankel
French
Gandhi
Greater Hobart
Hakama
Homeostasis
Hooge
Immune System
Immunology
Incidence
Inflammation
Innate Immune System
Interplay
Italy
Korn
Lalor
Lancet
Mahad
Manitoba
Marmoset
Mayr
Meta Analysis
Microglia
Minden
Minnesota
Mortality
Multiple Sclerosis
Myelopathy
Nathoo
Neurodegeneration
Neurology
Newcastle
Norway
Olmsted County
Padua
Paris
Pathogenesis
Pathology
Poser
Progressive
Province
Salemi
Sanai
Sci
Senescence
Srinath
Tasmania
United States
Warren G
White Matter

Semantics

Type Source Name
drug DRUGBANK Glatiramer
drug DRUGBANK Fingolimod
drug DRUGBANK Gold
gene UNIPROT RIOX2
disease DOID autoimmune disease
disease MESH autoimmune disease
disease MESH demyelination
disease MESH infections
gene UNIPROT ATG5
disease MESH hyperlipidemia
drug DRUGBANK Interferon beta-1a
drug DRUGBANK Natalizumab
drug DRUGBANK Alemtuzumab
disease DOID relapsing-remitting multiple sclerosis
disease MESH relapsing-remitting multiple sclerosis
disease MESH relapse
pathway BSID Release
gene UNIPROT ZBTB8OS
disease MESH community
gene UNIPROT MENT
drug DRUGBANK Trestolone
disease MESH depression
disease MESH development
disease DOID heart disease
disease MESH heart disease
disease MESH cognitive decline
disease MESH risk factors
gene UNIPROT TECR
disease MESH Cerebral small vessel disease
disease DOID hypertension
gene UNIPROT BDNF
gene UNIPROT NGF
gene UNIPROT GDNF
gene UNIPROT CYREN
gene UNIPROT MAGEE1
gene UNIPROT F11R
gene UNIPROT ST3GAL5
disease MESH atrophy
gene UNIPROT EGR3
drug DRUGBANK Ceramide NP
disease MESH primary progressive multiple sclerosis
disease DOID primary progressive multiple sclerosis
disease MESH disease progression
disease MESH stroke
disease DOID stroke
disease MESH type 1 diabetes
disease MESH cardiovascular diseases
disease MESH hypertension
gene UNIPROT DUOXA1
gene UNIPROT INTU
disease MESH complications
drug DRUGBANK Iron
gene UNIPROT BRD2
gene UNIPROT TNIP1
disease MESH inflammation
drug DRUGBANK Ethanol
drug DRUGBANK Mitoxantrone
gene UNIPROT RNF31
drug DRUGBANK Memantine
drug DRUGBANK Donepezil
drug DRUGBANK Ribostamycin
gene UNIPROT SH3PXD2A
gene UNIPROT NSMAF
gene UNIPROT YES1
gene UNIPROT ELAVL1
gene UNIPROT CNTRL
drug DRUGBANK Ocrelizumab
gene UNIPROT STMN1
gene UNIPROT IMPACT
drug DRUGBANK Polyethylene glycol
gene UNIPROT TMEM121
disease DOID secondary progressive multiple sclerosis
drug DRUGBANK Teriflunomide
drug DRUGBANK Siponimod
gene UNIPROT EHD1
disease MESH Mult
disease DOID multiple sclerosis
disease MESH multiple sclerosis
pathway BSID Immune System
pathway BSID Innate Immune System
gene UNIPROT COL9A3
gene UNIPROT COMP
gene UNIPROT COL9A1
gene UNIPROT COL9A2
gene UNIPROT SCN8A
gene UNIPROT EXOG
gene UNIPROT MBNL1
disease MESH experimental autoimmune encephalomyelitis
gene UNIPROT AMACR
disease MESH diagnosis
disease MESH comorbidity
gene UNIPROT ZNF746
gene UNIPROT UBXN11
disease DOID myelopathy
disease MESH myelopathy
gene UNIPROT OXCT2
pathway BSID Aging
disease MESH aging
gene UNIPROT FANCE
gene UNIPROT ELOVL6
disease DOID face
gene UNIPROT ACTA1
gene UNIPROT LARGE1
disease MESH cause of death
gene UNIPROT GTF2IRD1

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *